Investment Thesis
Inhibitor Therapeutics is in severe financial distress with negative stockholders' equity of -$1.3M, indicating liabilities exceed assets. The company generates zero revenue while burning $3.2M annually in operating cash flow with no clear path to profitability. With only $2.4M in cash and mounting losses, the company faces imminent solvency risk absent immediate capital injection or strategic intervention.
Strengths
- Adequate short-term liquidity with 3.19x current ratio relative to immediate obligations
- Minimal long-term debt burden of only $36.9K reducing refinancing risk
- Cash position of $2.4M provides brief runway for operations
Risks
- Negative stockholders' equity of -$1.3M indicates technical insolvency and shareholder value erosion
- Zero revenue generation with $3.4M operating losses demonstrates business model failure
- Negative free cash flow of -$3.2M at current cash levels provides only 9 months of runway before insolvency
- No insider buying activity suggests management lacks confidence in turnaround prospects
- Pharmaceutical sector requires substantial R&D investment with no indication of product pipeline advancement
Key Metrics to Watch
- Cash balance depletion rate and months of runway remaining
- Revenue recognition milestones from pipeline or partnerships
- Stockholders' equity recovery trajectory and capital raising activities
Financial Metrics
Revenue
0.0
Net Income
-3.3M
EPS (Diluted)
$-0.02
Free Cash Flow
-3.2M
Total Assets
2.5M
Cash
2.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-131.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
3.19x
Quick Ratio
3.19x
Debt/Equity
N/A
Debt/Assets
151.4%
Interest Coverage
-147.48x
Long-term Debt
36.9K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-29T11:00:10.440510 |
Data as of: 2025-12-31 |
Powered by Claude AI